進行非小細胞肺癌におけるゲノム医療の臨床開発

1)

Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H and Suga M : Diffuse alveolar damage

after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. 40 : 339-342, 2003.

2) Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y and Fukuoka M : Predictive

factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients

treated with gefitinib. Journal of Clinical Oncology. 24 : 2549-2556, 2006.

3) Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM,

Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA : Activating mutations in the

epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N

Engl J Med. 350 : 2129-39. 2004.

4) Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki

5)

6)

7)

8)

9)

K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M : EGFR mutations in lung cancer :

correlation with clinical response to gefitinib therapy. Science. 304 : 1497-500. 2004.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E,

Kupfer D, Wilson R, Kris M and Varmus H : EGF receptor gene mutations are common in lung cancers from

ânever smokersãand are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U

S A. 101 : 13306-11. 2004.

Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M and Nakagawa K :

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells

bearing EGFR gene mutation and amplification. Cancer Research. 67 : 2046-2053, 2007.

Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T,

Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T and Fukuoka M : Multicentre prospective phase II trial of

gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations : results of

the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer. 98 : 907-914, 2008.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T,

Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa

K and Fukuoka M ; for the West Japan Oncology Group : Gefitinib versus cisplatin plus docetaxel in patients

with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor

(WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncology. 11 : 121-128, 2010.

Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T,

Atagi S, Shibata K, Saito H, Toyooka S, Yamamoto N, Nakagawa K and Mitsudomi T : Final overall survival

results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the

first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive

non-small-cell lung cancer. Annals of Oncology. 30 : 1978-1984, 2019.

（特に重要な文献については，番号をゴシック体で表記している．）

著者プロフィール

岡本 勇（おかもと いさむ)

九州大学教授（大学院医学研究院呼吸器内科学）．医学博士

◆略歴 1966 年福岡県に生まれる．1992 年熊本大学医学部卒業．1999 年同大学院医学研究科博士

課 程 修 了．1999 年 米 国 National Cancer Institute, 2000 年 米 国 Thomas Jefferson Univ.

Kimmel Cancer Institute. 2007 年近畿大学医学部内科学腫瘍内科部門准教授．2013 年九州

大学病院呼吸器科・ARO 次世代医療センター特任准教授．2015 年九州大学病院 診療准

教授．2021 年 11 月より現職

◆研究テーマと抱負 難治性呼吸器疾患の病態を制御する分子機構を探索し，基礎研究で得られた

成果を科学的・倫理的に妥当で精度の高い臨床研究によって臨床導入を試みて参ります．

◆趣味 山登り，スポーツ観戦

肺がんゲノム医療の進歩

Clinical Development for Cancer Genome Medicine

in Advanced Non-Small-Cell Lung Cancer

Isamu OKAMOTO

Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University

Abstract

âCancerãis the leading cause of death in Japan. Among them, lung cancer is the leading cause of

cancer death, and more than 70,000 patients die annually in Japan. Despite of lung cancer medical

examination in Japan, more than half of them are inoperable advanced lung cancer with distant

metastasis at the time of diagnosis, and for those patients, treatment with anticancer drugs is indicated.

The treatment outcome for advanced lung cancer was extremely severe 20 years ago, with a median

survival time of 12-15 months. However, in recent years, the introduction of molecular-targeted

therapy based on genetic abnormalities has significantly improved treatment results, and many cases

have been experienced in which daily life can be maintained for more than 5 years.

This long-term progress in lung cancer treatment is based on the results of excellent basic

molecular biology research and it is also noteworthy that the accumulation of high-quality

investigator-initiated clinical trials have led to improved treatment results. Here, I am going to

introduce how lung cancer drug treatment has progressed and what role investigator-initiated clinical

trials have played in it, including a part of our research.

Key words : lung cancer, molecular-targeted therapy, clinical trial

...